K 01-162 is primarily investigated for its potential in cancer therapy. It functions as a potent inhibitor of specific kinases involved in cell proliferation and survival pathways, making it a promising candidate for targeting various types of cancers. Research has shown its efficacy in disrupting tumor growth and inducing apoptosis in cancer cells, particularly in cases where traditional treatments have limited success. Additionally, its ability to modulate signaling pathways offers potential for combination therapies, enhancing the effectiveness of existing chemotherapeutic agents. Ongoing studies aim to explore its application in personalized medicine, particularly for cancers with specific genetic mutations or resistance mechanisms.